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How meals become bones
 
mylin, a hormone produced along with insulin after food 
intake, is vital for strengthening bones, according to Dacquin 
et al. (page 509). A lack of amylin production in type I
(autoimmune) diabetics may explain the prominent bone loss 
in these individuals—a problem that amylin replacement 
therapy may alleviate.
When food is short, strengthening bone may not be the body’s 
top priority. But when the food arrives it is time to build up 
bone mass. After food enters the digestive tract, amylin is 
cosecreted with insulin from pancreatic islet cells, but there is 
no known function for amylin in glucose metabolism. In the 
new work, the authors found that mice lacking either one or 
both copies of the amylin gene have normal appetites, but 
exhibit low bone mass and an increased number of bone-chewing 
osteoclasts. Ex vivo analysis of bone marrow macrophages 
from the mutant mice shows that amylin specifically regulates 
osteoclast differentiation.
Previous work had shown that amylin can bind to the calcitonin 
receptor in vitro, but the new study shows that heterozygous 
calcitonin receptor deletion increases bone mass, exactly opposite 
to the amylin knockout phenotype. Mice with heterozygous 
deletions in both calcitonin receptor and amylin genes show 
both increased osteoclast numbers and increased bone formation, 
with bone formation enjoying a slight edge.
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A primordial mover for sphingolipids
 
n people with Niemann Pick Type C 
disease (NP-C), a fatal neurodegenera-
tive disorder, both sphingolipids and 
cholesterol accumulate in lysosomes, 
but controversy swirls around which 
of these metabolites causes the disease. 
On page 547, Malathi et al. present
evidence that NPC1, the protein that is 
defective in most NP-C patients, may 
have evolved primarily to transport 
sphingolipids, as it can be replaced by 
a yeast version with only the sphingolipid 
functionality. The data favor the idea 
that sphingolipids are the offending 
metabolite in NP-C, and suggest that 
a redundant pathway for sphingolipid 
transport could be an attractive target 
for novel NP-C therapies.
Chinese hamster ovary cells lacking 
NPC1 exhibit aberrant sphingolipid and 
cholesterol accumulation. In the new 
work, the authors found that expressing 
NCR1, the yeast orthologue of NPC1, 
repairs all of the lipid transport defects 
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Based on the results, Dacquin et al. propose that amylin, 
using a receptor other than the calcitonin receptor, regulates 
bone resorption by inhibiting the differentiation of osteoclasts. 
In patients with Type 1 diabetes, the absence of pancreatic islet 
cells should severely reduce the secretion of amylin, which 
would explain the bone loss associated with that disease. The 
authors are now trying to identify the real amylin receptor, 
and hope to use the new mouse model to search for therapies 
for diabetes-associated osteoporosis. 
 
 
Mice lacking amylin have low bone mass (right).
 
in these mammalian cells. Functional 
conservation across a billion years 
of evolution is especially surprising in 
this case, since yeast do not engage 
in receptor-mediated transport of 
exogenous cholesterol.
Extraordinary conservation implies a 
Metabolites mislocalize to lysosomes 
(blue) except in cells with NCR1 (green).
 
critical function, but deleting NCR1 in 
yeast cells has no detectable effect on 
sterol metabolism. A dominant–negative 
mutation in the conserved putative 
sterol-sensing domain of NCR1, how-
ever, causes pronounced sphingolipid 
trafficking defects in yeast without 
affecting sterol trafficking. NCR1 and 
its homologues appear to share a 
primordial function in sphingolipid 
transport, and it is possible that defects 
in cholesterol transport in NP-C are simply 
a byproduct of the close association 
of cholesterol with sphingolipids in 
membrane rafts.
The lack of a phenotype in NCR1-null 
yeast cells also indicates that some 
other sphingolipid transport pathway 
must be able to compensate for the loss 
of NCR1. The authors are now trying to 
identify NCR1 binding proteins and to 
elucidate the alternate pathway, efforts 
that could uncover novel therapeutic 
targets for the treatment of NP-C.
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